A lawsuit has been filed against PACS Group, Inc. accusing the company of engaging in fraudulent Medicare billing practices from 2020 to 2023, which allegedly accounted for all of its operating and net income during that period. The complaint claims PACS submitted false Medicare claims, billed unnecessary therapies, and falsified licensing and staffing documents, misleading investors about the company's true business condition. The case is currently pending, with defendants having filed a motion to dismiss in early 2026. Investors who bought PACS shares before April 2024 and still hold them are advised to contact the Shareholders Foundation for options regarding the lawsuit.
In Austria, selling Bitcoin directly between private individuals is taxed the same as sales via crypto exchanges. The taxable event is the capital gain—the difference between sale proceeds and acquisition cost—with a 27.5% tax rate for Bitcoin acquir...
The U.S. SEC has approved Evernorth's registration, clearing the way for its $1 billion Nasdaq listing under the ticker XRPN through a merger with Armada Acquisition Corp. II. Evernorth plans to actively manage its XRP treasury to generate yield and ...
Amprius Technologies is benefiting from strong demand for drone batteries, reporting a 125.7% year-over-year revenue increase and improved gross margins. The company raised its 2026 revenue forecast to at least $140 million and aims for $600 million ...
INmune Bio is considered significantly undervalued with its treatment Ebstrocel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) driving a strong investment case. Ebstrocel offers systemic itch reduction, setting it apart from competitors like K...
PayPal's stock dropped sharply by 14.67% to $52.45 after Stripe and Advent withdrew their $60.50 per share acquisition offer, causing the company's market value to fall from $52.58 billion to $44.87 billion. This reversal ended the summer rally drive...
